Slide 1: Investor Presentation
22 S E PT E M BE R 2026 INVESTOR PRESENTATION S teve n Lyde a m ore - C EO NASDAQ: IMRN ASX: IMC
Slide 2: Safe Harbor Statement
Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “ anticipates,” “expects,” “intends,” “plans,” “believes,” “ seeks,” “estimates,” “guidance” and s imilar expressions are intended t
Slide 3: Immuron Ltd company overview and financial snapshot
Immuron Ltd is an Australian integrated biopharmaceutical company with global scale, focused on developing, and commercialising, oral products for the treatment of gut mediated diseases Research & Development 2 pipeline assets to be partnered for development and commercialization Global footprint Au
Slide 4: FY26 Financial Achievements
4 FY26 Financial Achievements Global Sales Revenue $7.7m Up 6% Australian Sales Revenue $5.8m Up 10% United States Sales Revenue $1.8m Up 7% Up 13% in $USD Gross Profit Margin 64.5% 0.9% decline Net Profit $(3.8)m $1.4m improvement Cash $9.0m $6.2m 1 improvement 1. $3.0 million was held in Term Depo
Slide 5: FY26 Clinical Achievements and Operational Highlights
5 FY26 Clinical Achievements and Operational Highlights FDA approval IMM - 529 IND Travelan® n= 851 trial completed New U.S. Department of Defense subaward New product launch in Australia Engaged Pullan Consulting to support partnering IMM - 529 Strategic reset aimed at profitability and reduced cas
Slide 6: FY27 Outlook
6 FY27 Outlook Continued Travelan® sales growth Portfolio expansion Geographic sales expansion Partnering update for IMM - 529 Cash to fund operations through FY27 – FY28 Continued improvement in profitability and reduced cash burn
Slide 7: Immuron strategic reset provides clearer path to profitability
7 Immuron strategic reset provides clearer path to profitability Immuron has taken a strategic decision to partner clinical assets IMM - 124E and IMM - 529 for development and commercialization. • IMM - 124E is eligible for an end of Phase 2 meeting with the U.S. FDA (indication: traveler’s diarrhea
Slide 8: A First-in-Class Triple-Action CDI Biologic
8 IMM - 529: A First - in - Class Triple - Action CDI Biologic The Opportunity : IMM - 529 is an oral, non - systemic biological (hyperimmune bovine colostrum) for treatment and prevention of primary and recurrent Clostridioides difficile infection (CDI). Unlike antibiotics, IMM - 529 eliminates the
Slide 9: The Disease: C. difficile and market opportunity
The Disease: C. difficile is the leading cause of healthcare - associated infection causing 400,000 cases and 30,000 deaths in the US annually Disease spectrum: • Mild - to - moderate : Watery persistent diarrhea, cramping • Severe/Pseudomembranous Colitis (PMC) : Colon wall plaques • Fulminant CDI
Slide 10: Deal Potential: comparable CDI licensing deals
10 IMM - 529 Deal Potential Status update (as of March 2026) Stage at deal Financial terms (public) Licensed Asset Licensee / Acquirer Licensor / Asset Owner Year FDA approved (Apr 2023) and commercialized by Nestlé Health Science; global rights consolidated under Nestlé via the 2024 transaction. (
Slide 11: Institutional Investor Snapshot
IMMURON LIMITED (ASX:IMC / Nasdaq:IMRN) | Institutional Investor Snapshot FY2026 Revenue A$7.7m FY26 +6% YoY Market Cap. A$14.85m 17 September 2026 Cash A$9.0m @30 June 26; 24 - month runway Pipeline 2 Assets Partnering focus Investment Thesis • Commercial - stage biotech with recurring OTC revenue
Slide 12: Contact Information
EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: